Canine osteosarcoma: Results of amputation with and without adjuvant immunotherapy

Summary Forty-eight dogs with spontaneously occurring osteogenic sarcoma (OS) were treated by amputation. Six dogs died soon after surgery, 34 dogs died or were euthanized 1–11 (median 4) months after, and eight dogs (17%) are alive 11–47 (median 21) months after amputation. Thirty-one dogs did not receive any therapy after amputation. Seventeen dogs received postamputation adjuvant immunotherapy consisting of intradermal bacillus Calmette-Guerin and an autologous tumor homogenate preparation administered every other week for 12 weeks. Twelve of these dogs were included in a prospectively randomized therapeutic trial in which a control group of 11 dogs received no therapy after amputation. Neither disease-free interval nor survival was prolonged by the immunotherapy protocol. Nevertheless, the current study demonstrates the feasibility of studying naturally occurring canine OS as a clinical and therapeutic model for OS in man.